New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23382112.
- Also identified by DOI 10.1158/1078-0432.CCR-12-3796.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice.
Medical subject headings
- Carcinoma, Hepatocellular
- Guidelines as Topic
- Liver Neoplasms
- Survival Analysis